{"id":985707,"date":"2026-07-28T10:23:52","date_gmt":"2026-07-28T14:23:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wgs-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-genedx-holdings-corp-securities-lawsuit-contact-suewallst\/"},"modified":"2026-07-28T10:23:52","modified_gmt":"2026-07-28T14:23:52","slug":"wgs-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-genedx-holdings-corp-securities-lawsuit-contact-suewallst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wgs-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-genedx-holdings-corp-securities-lawsuit-contact-suewallst\/","title":{"rendered":"WGS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GeneDx Holdings Corp. Securities Lawsuit – Contact SueWallSt"},"content":{"rendered":"

\nGeneDx Promised Fabric Genomics Would “Transform Static Data Into Recurring Revenue” and “Unlock Software-Based Revenue Streams” \u2014 Instead, Investors Got a $31.2 Million Write-Off and a 49% Stock Collapse
\n<\/h2>\n
\n

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) — SueWallSt highlights the contrast between GeneDx Holdings Corp.’s (NASDAQ: WGS) promises to investors and the actual results of its Fabric Genomics acquisition. Shareholders who purchased WGS securities between April 16, 2025 and May 4, 2026 and suffered losses may be entitled to compensation. Check if you might be eligible to recover your investment losses<\/u><\/a> or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/u><\/a> or (888) SueWallSt.<\/p>\n

On May 5, 2026, WGS shares closed at $34.51, down $33.42 per share (49.20%) from the prior close, after the Company revealed the full scope of Fabric’s failure. The lead plaintiff deadline is August 3, 2026.<\/p>\n

The promise: “Fabric Genomics’ software transforms static data into a dynamic, recurring revenue-generating platform \u2014 driving growth through software margins and high-leverage interpretation services across geographies and clinical use cases.”<\/p>\n

The reality: a $31.2 million impairment charge, an admission that Fabric was suited only for international markets, and a $65 million reduction in full-year revenue guidance.<\/p>\n

\n The Promise: A “Recurring Revenue” Engine<\/strong>\n <\/p>\n

When GeneDx announced the Fabric Genomics acquisition on April 16, 2025, the Company projected multiple scalable revenue streams, software-driven margins, and a platform that would strengthen its competitive position across geographies. On the Q2 2025 earnings call, management described Fabric as on track with revenue and gross margin plans, called the collaboration “fantastic,” and said there was “room to run” in reducing costs by combining the two companies’ capabilities.<\/p>\n

\n The Reality: A $31.2 Million Write-Off<\/strong>\n <\/p>\n

On May 4, 2026, GeneDx disclosed that Fabric had failed to meet the goals management had repeatedly touted. The Company wrote down $31.2 million in goodwill and intangible assets tied to Fabric and admitted the platform was best suited only for international markets, not the broad domestic and global application previously described. Full-year revenue guidance dropped from $540-$555 million to $475-$490 million.<\/p>\n

\n The Numbers: Promised vs. Actual<\/strong>\n <\/p>\n